Considering the latest report in the field of tumor immunology, the TIGIT/CD155/DNAM-1 pathway plays the predominant role in OC progression and interactions of its components with the programmed cell death pathway create strong immunosuppression in the ovarian cancer TME. Here, CD226 is linked to ovarian carcinoma.